15.4  -0.1 (-0.65%)		10-14 16:00
Open: 15.25 High: 16.195 Volume: 137,815		Pre. Close: 15.5 Low: 15.25 Market Cap: 226(M)

Short term
Mid term
Targets	6-month :	20.93	1-year :	23.71
Resists	First :	17.92	Second :	20.3
Pivot price	16.94
Supports	First :	14.06	Second :	11.69
MAs	MA(5) :	16.06	MA(20) :	17.35
	MA(100) :	18.52	MA(250) :	19.53
MACD	MACD :	-0.3	Signal :	-0.1
%K %D	K(14,3) :	36.2	D(3) :	36.2
RSI	RSI(14): 43.2
52-week	High :	34.09	Low :	7.78

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GLSI ] has closed above bottom band by 17.8%. Bollinger Bands are 26.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	16.2 - 16.31	16.31 - 16.4
Low:	15.05 - 15.15	15.15 - 15.24
Close:	15.25 - 15.42	15.42 - 15.55

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Mon, 12 Oct 2026
Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones - Stock Traders Daily

Thu, 01 Oct 2026
Greenwich Lifesciences Inc (GLSI-Q) Stock Price and News - The Globe and Mail

Tue, 21 Jul 2026
Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me - Seeking Alpha

Mon, 20 Jul 2026
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 - GlobeNewswire

Thu, 16 Jul 2026
Greenwich LifeSciences The Overlooked Need (NASDAQ:GLSI) - Seeking Alpha

Thu, 25 Jun 2026
GLSI Forecast — Price Target — Prediction for 2027 - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	15 (M)
Shares Float	8 (M)
Held by Insiders	47.9 (%)
Held by Institutions	12.2 (%)
Shares Short	1,580 (K)
Shares Short P.Month	1,660 (K)

EPS	-1.53
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.2
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-236 %
Return on Equity (ttm)	-986.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.55
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-10.07
PEG Ratio	0
Price to Book value	73.33
Price to Sales	0
Price to Cash Flow	-18.11

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.